Teva Pharmaceuticals vs Universe Pharmaceuticals
Universe Pharmaceuticals reported revenue of $17.9 billion in fiscal 2025, about the same as Teva Pharmaceuticals' $17.3 billion in fiscal 2025. Teva Pharmaceuticals' revenue grew 4.3% in its latest year, and Universe Pharmaceuticals' fell 22.4%. Teva Pharmaceuticals had an operating margin of 12.5%, against -16.3% at Universe Pharmaceuticals. Free cash flow was $1.1 billion at Teva Pharmaceuticals and −$5.3 billion at Universe Pharmaceuticals. Their fiscal years end in different months (December 31 and September 30), so the periods don't line up exactly.
Side by side
| Teva Pharmaceuticals | Universe Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Sep 30, 2025 |
| Revenue | $17.3B | $17.9B |
| Revenue growth | 4.3% | −22.4% |
| Revenue growth a year, last 5 years | 0.7% | 257.2% |
| Gross margin | 51.8% | 35.3% |
| Operating margin | 12.5% | −16.3% |
| Net margin | 8.2% | −20.6% |
| Free cash flow | $1.1B | −$5.3B |
| Free cash flow margin | 6.7% | −29.8% |
| Return on capital | 10.5% | — |
| Net debt to EBITDA | 4.2x | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 2.8% | 3,174.9% |
| Last close | $38.54 | $1.36 |
| P/E at the last close | 89.6× | — |
| Insider trades, last 12 months | sold $125.1 million | — |
| Piotroski F-score | 8 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Teva PharmaceuticalsUniverse Pharmaceuticals
Operating margin
Percent of revenue
Teva PharmaceuticalsUniverse Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Teva PharmaceuticalsUniverse Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Teva Pharmaceuticals and Universe Pharmaceuticals pages.